{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:27:53Z","timestamp":1790245673435,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40264-022-01194-z","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T15:04:09Z","timestamp":1657724649000},"page":"891-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0254-2212","authenticated-orcid":false,"given":"Michele","family":"Fusaroli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Isgr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6937-4495","authenticated-orcid":false,"given":"Paola Maria","family":"Cutroneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-6548","authenticated-orcid":false,"given":"Carmen","family":"Ferrajolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9643-3465","authenticated-orcid":false,"given":"Francesca","family":"Del Bufalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7996","authenticated-orcid":false,"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7209-0426","authenticated-orcid":false,"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-7296","authenticated-orcid":false,"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"1194_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1194_CR2","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Sch\u00fc\u00dfler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9:1183\u201397.","journal-title":"EMBO Mol Med"},{"key":"1194_CR3","unstructured":"US FDA. FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. 2019. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma. Accessed 26 Jun 2022."},{"key":"1194_CR4","unstructured":"US FDA. FDA approves axicabtagene ciloleucel for large B-cell lymphoma. 2019. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma. Accessed 26 Jun 2022."},{"key":"1194_CR5","unstructured":"European Medicines Agency. First two CAR-T cell medicines recommended for approval in the European Union. 2018. https:\/\/www.ema.europa.eu\/en\/news\/first-two-car-t-cell-medicines-recommended-approval-european-union. Accessed 26 Jun 2022."},{"key":"1194_CR6","unstructured":"US FDA. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome. Accessed 26 Jun 2022."},{"key":"1194_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"1194_CR8","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"1194_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"1194_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy: assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1194_CR11","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321\u201330.","journal-title":"Blood"},{"key":"1194_CR12","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/S1470-2045(19)30729-6","volume":"21","author":"M Elsallab","year":"2020","unstructured":"Elsallab M, Levine BL, Wayne AS, Abou-El-Enein M. CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncol. 2020;21:e104\u201316.","journal-title":"Lancet Oncol"},{"key":"1194_CR13","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74:3099\u2013108.","journal-title":"J Am Coll Cardiol"},{"key":"1194_CR14","doi-asserted-by":"crossref","unstructured":"Gajra A, Zettler ME, Phillips EG, Klink AJ, Jonathan KK, Fortier S, et al. Neurological adverse events following CAR T-cell therapy: a real-world analysis. Immunotherapy. 2020;12:1077\u201382.","DOI":"10.2217\/imt-2020-0161"},{"key":"1194_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/ph13090258","volume":"13","author":"C Rafaniello","year":"2020","unstructured":"Rafaniello C, Ferrajolo C, Gaio M, Zinzi A, Scavone C, Sullo MG, et al. Tisagenlecleucel in children and young adults: reverse translational research by using real-world safety data. Pharmaceuticals (Basel). 2020;13:258.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1194_CR16","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00228-021-03106-z","volume":"77","author":"G Bonaldo","year":"2021","unstructured":"Bonaldo G, Montanaro N, Alberto V, Motola D. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice. Eur J Clin Pharmacol. 2021;77:1225\u201334.","journal-title":"Eur J Clin Pharmacol"},{"key":"1194_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10:796\u2013803.","journal-title":"Int J Med Sci"},{"key":"1194_CR18","doi-asserted-by":"publisher","unstructured":"Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible fda adverse event reporting system (AERS). In: Karahoca A., editor. Data mining applications in engineering and medicine [Internet]. London: IntechOpen; 2012. Available from: https:\/\/www.intechopen.com\/chapters\/38579. https:\/\/doi.org\/10.5772\/50095.","DOI":"10.5772\/50095"},{"key":"1194_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/pds.3933","volume":"25","author":"RF Reynolds","year":"2016","unstructured":"Reynolds RF, Kurz X, de Groot MCH, Schlienger RG, Grimaldi-Bensouda L, Tcherny-Lessenot S, et al. The IMI PROTECT project: purpose, organizational structure, and procedures. Pharmacoepidemiol Drug Saf. 2016;25:5\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1194_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","volume":"15","author":"E Raschi","year":"2020","unstructured":"Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Target Oncol. 2020;15:449\u201366.","journal-title":"Target Oncol"},{"key":"1194_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369.","journal-title":"Stat Methods Med Res"},{"key":"1194_CR22","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1038\/srep05918","volume":"4","author":"CD van Borkulo","year":"2014","unstructured":"van Borkulo CD, Borsboom D, Epskamp S, Blanken TF, Boschloo L, Schoevers RA, et al. A new method for constructing networks from binary data. Sci Rep. 2014;4:5918.","journal-title":"Sci Rep"},{"key":"1194_CR23","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.3389\/fphar.2021.740707","volume":"12","author":"M Fusaroli","year":"2021","unstructured":"Fusaroli M, Raschi E, Gatti M, De Ponti F, Poluzzi E. Development of a network-based signal detection tool: the COVID-19 Adversome in the FDA Adverse Event Reporting System. Front Pharmacol. 2021;12:3542.","journal-title":"Front Pharmacol"},{"key":"1194_CR24","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","volume":"26","author":"A Guha","year":"2020","unstructured":"Guha A, Addison D, Jain P, Gutierrez JM, Ghosh A, Roddie C, et al. Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-sectional FDA Adverse Events Reporting System analysis. Biol Blood Marrow Transplant. 2020;26:2211\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1194_CR25","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/ajh.26259","volume":"96","author":"C Dolladille","year":"2021","unstructured":"Dolladille C, Ederhy S, Ezine E, Choquet S, Nguyen LS, Alexandre J, et al. Chimeric antigen receptor T-cells safety: a pharmacovigilance and meta-analysis study. Am J Hematol. 2021;96:1101\u201311.","journal-title":"Am J Hematol"},{"key":"1194_CR26","unstructured":"National Cancer Institute, SEER. Diffuse large B-cell lymphoma: cancer stat facts. 2021. https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html. Accessed 2 Nov 2021."},{"key":"1194_CR27","unstructured":"National Cancer Institute, SEER. Acute lymphocytic leukemia: cancer stat facts. 2021. https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html. Accessed 2 Nov 2021."},{"key":"1194_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jgo.2020.07.006","volume":"12","author":"ME Zettler","year":"2021","unstructured":"Zettler ME, Feinberg BA, Phillips EG, Klink AJ, Mehta S, Gajra A. Real-world adverse events associated with CAR T-cell therapy among adults age \u2265 65 years. J Geriatr Oncol. 2021;12:239\u201342.","journal-title":"J Geriatr Oncol."},{"key":"1194_CR29","first-page":"1501","volume":"12","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Z, Ren Z, Li Y. Reactions related to CAR-T cell therapy. Front Immunol. 2021;12:1501.","journal-title":"Front Immunol"},{"issue":"35","key":"1194_CR30","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"9","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;9(35):3978\u201392.","journal-title":"J Clin Oncol"},{"key":"1194_CR31","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318.","journal-title":"N Engl J Med"},{"key":"1194_CR32","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709\u201320.","journal-title":"Blood"},{"key":"1194_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet"},{"key":"1194_CR34","first-page":"3636","volume":"61","author":"A Fischer","year":"2020","unstructured":"Fischer A, Li A. CAR T-cell therapy associated ocular adverse events reported to the Food and Drug Administration. Invest Ophthalmol Vis Sci. 2020;61:3636.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1194_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1182\/blood-2018-99-112023","volume":"132","author":"A Cordeiro","year":"2018","unstructured":"Cordeiro A, Bezerra ED, Hill JA, Turtle CJ, Maloney DG, Bar M. Late effects of CD19-targeted CAR-T cell therapy. Blood. 2018;132:223.","journal-title":"Blood"},{"key":"1194_CR36","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","volume":"142","author":"S Ganatra","year":"2020","unstructured":"Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, et al. Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation. 2020;142:1687\u201390.","journal-title":"Circulation"},{"key":"1194_CR37","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bjh.13965","volume":"173","author":"KB Smeland","year":"2016","unstructured":"Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli U-M, Falk RS, et al. A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. Br J Haematol. 2016;173:432\u201343.","journal-title":"Br J Haematol"},{"key":"1194_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cncr.21971","volume":"107","author":"JD Tward","year":"2006","unstructured":"Tward JD, Wendland MMM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107:108\u201315.","journal-title":"Cancer"},{"key":"1194_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1027469","volume":"4","author":"H Dai","year":"2015","unstructured":"Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. OncoImmunology. 2015;4: e1027469.","journal-title":"OncoImmunology."},{"key":"1194_CR40","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255\u201373.","journal-title":"N Engl J Med"},{"key":"1194_CR41","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bjh.15644","volume":"183","author":"KA Hay","year":"2018","unstructured":"Hay KA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol. 2018;183:364\u201374.","journal-title":"Br J Haematol"},{"key":"1194_CR42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433\u201344.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1194_CR43","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi L-A, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130:2295\u2013306.","journal-title":"Blood"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01194-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01194-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01194-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T12:32:55Z","timestamp":1659961975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01194-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1194"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01194-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"29 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MF, VI, PC, CF, FD, VC, and EP declare that they have no conflicts of interest. ER reports a personal fee for consultancy from Novartis, outside the submitted work. GT has served on advisory boards, seminars, masters, and projects funded by several pharmaceutical companies (Eli Lilly, Amgen, Sanofi, SOBI, Gilead, PTC Therapeutics, ABBvie, Verpora, Daiichi Sankyo), outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Anonymized data were collected from a publicly available database and do not require ethics committee approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available in the US FAERS repository.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The R script developed for the analyses is available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MF, VI, PC, CF, ER, FD, VC, ER, EP, and GT conceived and executed the research project. MF designed and executed the statistical analysis. MF, VI, PC, CF, ER, EP, and GT reviewed and critiqued the statistical analysis. All the authors contributed to the interpretation of data. Regarding article preparation, the writing of the first draft was executed by MF and VI, and all the authors contributed to the review and critique. All the authors approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}